Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NOX4 | Q9NPH5 | 5/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.33 |
| ▸ | PARG | Q86W56 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9278215 | 0.76 | NQO2 (0.42) | NQO2KDM4ENOX4CYP19A1ALDH1A1 | |
| SCHEMBL589818 | 0.76 | NOX4 (0.40) | NQO2KDM4ENOX4CYP19A1ALDH1A1 | |
| SCHEMBL11854311 | 0.73 | IDH1 (0.37) | NQO2KDM4EALDH1A1MAPK1 | |
| SCHEMBL23341812 | 0.73 | NQO2 (0.40) | NQO2KDM4ENOX4CYP19A1ALDH1A1 | |
| SCHEMBL21937407 | 0.73 | NOX4 (0.42) | NQO2KDM4ENOX4CYP19A1ALDH1A1 | |
| SCHEMBL22996820 | 0.73 | AR (0.40) | NOX4 | |
| SCHEMBL21826182 | 0.72 | ALDH1A1 (0.48) | NQO2KDM4ENOX4CYP19A1ALDH1A1 | |
| SCHEMBL16672604 | 0.70 | MAPT (0.38) | KDM4EALDH1A1GAA | |
| SCHEMBL26555530 | 0.70 | CYP19A1 (0.55) | NQO2KDM4ENOX4CYP19A1KAT2B | |
| SCHEMBL12149746 | 0.70 | KMT2A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021222069-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | INCELLDX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20080299132-A1 | Synergistic compositions for treating HIV-1 | ROCHE PALO ALTO LLC | 2008-12-04 | — | — | US | disclosed |
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191335-A1 | 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2007085567-A2 | SYNERGISTIC COMPOSITIONS FOR TREATING HIV | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191335-A1 | 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease | CCR5, CXCR1, CXCR3 | NQO2 2347/4885KDM4E 2455/4885NOX4 2098/4885 |
| US-20070191406-A1 | Heterocyclic antiviral compounds | CCR5, CX3CR1, CXCR1 | NQO2 1255/4885KDM4E 4003/4885NOX4 1433/4885 |
| US-20080299132-A1 | Synergistic compositions for treating HIV-1 | CCR5, CD4, HAVCR2 | NQO2 3517/4885KDM4E 4754/4885NOX4 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.